A novel mutation in ORAI1 presenting with combined immunodeficiency and residual T-cell function

J Allergy Clin Immunol. 2015 Aug;136(2):479-482.e1. doi: 10.1016/j.jaci.2015.03.050. Epub 2015 Jun 9.

Abstract

This study identifies a novel ORAI1 mutation that abolishes protein expression, but permits robust lymphocyte proliferation to mitogens. It is important to consider ORAI1 deficiency in the setting of a combined immunodeficiency with normal T cell numbers and residual T cell function.

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Calcium Channels / genetics
  • Calcium Channels / immunology*
  • Cell Proliferation / drug effects
  • Child
  • Consanguinity
  • Female
  • Fibroblasts / immunology*
  • Fibroblasts / pathology
  • Gene Expression
  • HEK293 Cells
  • Humans
  • Immunologic Deficiency Syndromes / diagnosis
  • Immunologic Deficiency Syndromes / genetics*
  • Immunologic Deficiency Syndromes / immunology
  • Immunologic Deficiency Syndromes / pathology
  • Ion Transport
  • Male
  • Mutation*
  • ORAI1 Protein
  • Pedigree
  • Primary Cell Culture
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / pathology
  • Tetradecanoylphorbol Acetate / pharmacology
  • Transfection

Substances

  • Calcium Channels
  • ORAI1 Protein
  • ORAI1 protein, human
  • Tetradecanoylphorbol Acetate